Syndax Pharmaceuticals, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +396.7%
EBITDA: +50.0%
EBIT: +35.0%
EPS: +27.6%
Free cash flow: +2.9%
Operating cash flow: +2.9%

Forward estimates

Revenue: -0.9%
EBITDA: +105.1%
EPS: +78.7%

Three-year CAGR

Revenue: +627.8%
EBITDA: +19.8%
EBIT: +19.6%
Net income: +10.5%
EPS: +11.8%
Free cash flow: -17.6%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.